Abstract
Recent investments may signal a revitalization for US-based drug services firms. With manufacturing capacity for active pharmaceutical ingredients (APIs) at a premium worldwide and the US government pushing to secure the domestic drug supply chain, US companies are ready to expand, industry watchers say. Cascade Chemistry, a contract development and manufacturing organization in Eugene, Oregon, is launching a $14 million expansion of its API manufacturing capacity in response to increased demand. Regis Technologies just completed new laboratories at its headquarters in Morton Grove, Illinois, that will double its development services capacity. And Phlow, a partnership that debuted last year with a $354 million US government grant to establish domestic supply of key generic drugs, has closed a $20 million financing round to support its commercial operations. “It’s all of the above,” says James Bruno, president of the consulting firm Chemical and Pharmaceutical Solutions, in assessing the market trends driving the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
